 |
|
Periocular Cutaneous Pigmentary Changes Associated With Bimatoprost Use
Arch Ophthalmol. 2005;123:1609-1610.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Topical bimatoprost (Lumigan; Allergan Inc, Irvine, Calif) is a prostamide analog licensed in the United States (2001) and in the United Kingdom (2002) as a second-line treatment modality for glaucoma and ocular hypertension. Unlike with latanoprost, there is little published evidence for any periocular skin pigmentary effects associated with bimatoprost. We herein report 3 cases of bimatoprost-related periorbital skin hyperpigmentation along with a review of the literature and a comparison with published latanoprost effects.
Report of Cases
Case 1. A 76-year-old white woman with normal-tension glaucoma in the left eye had been treated with 0.25% timolol eyedrops twice daily for 6 years. She was otherwise well and was receiving no other medication. Because of progressive optic disc damage, her treatment was changed to 0.03% bimatoprost eyedrops nightly in the left eye only. When followed up 2 months later, she commented that the skin around the left eye had become darker, developing an unsightly . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
Gavin D. Galloway, MRCOphth;
Tom Eke, FRCOphth, MD;
David C. Broadway, FRCOphth, MD
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Bimatoprost-Induced Periocular Skin Hyperpigmentation: Histopathological Study
Rashmi Kapur, Smajo Osmanovic, Sami Toyran, and Deepak P. Edward
Arch Ophthalmol. 2005;123(11):1541-1546.
ABSTRACT
| FULL TEXT
|
